BioPharma Dive staff's articles Biotechnology Lilly details MASH data for tirzepatide; Cytokinetics comments on past sale talks A study abstract shed more light on tirzepatide’s potential in MASH. Elsewhere, Cytokinetics CEO spoke on deal negotiations and AbbVie started a key multiple myeloma drug study. Written by BioPharma Dive staff June 5, 2024June 5, 2024 Saving Bookmark this article Bookmarked
Biotechnology Lilly details MASH data for tirzepatide; Cytokinetics comments on past sale talks A study abstract shed more light on tirzepatide’s potential in MASH. Elsewhere, Cytokinetics CEO spoke on deal negotiations and AbbVie started a key multiple myeloma drug study. Written by BioPharma Dive staff June 5, 2024June 5, 2024 Saving Bookmark this article Bookmarked
